natgillin/translations-raw huggingface dataset:
at least one sulfonate selected from the group consisting of an alkylbenzene sulfonate, an alkylnaphthalene sulfonate, an alkylbenzene sulfonate condensed with formaldehyde and an alkylnaphthalene sulfonate condensed with formaldehyde, and 
najmanje jedan sulfonat odabran iz skupine koju čine neki sulfonat, alkilnaftalen sulfonat, alkilbenzen sulfonat kondenziran s formaldehidom i alkilnaftalen sulfonat kondenziran s formaldehidom i
average diameter of 50% of the microcapsules: 4.5µm 
Broj objave europskog patenta:
Use of a kit of parts in a method of detecting HPV-induced high-grade precancerous lesion or HPV-induced invasive carcinoma in test cells from a cervico-vaginal lavage sample of a subject, said kit comprising a methylation sensitive restriction endonuclease and 
Upotreba kompleta dijelova u postupku detektiranja HPV-om prouzročene prekancerogene lezije visokog rizika ili HPV-om prouzročenog invazivnog karcinoma u testiranim stanicama iz uzorka cervikovaginalne lavaže ispitanika, navedeni komplet sadrži na metilaciju osjetljivu restriktivnu endonukleazu i
Solid pharmaceutical formulation according to claim 4, further comprising povidone, croscarmellose sodium, microcrystalline cellulose, colloidal anhydrous silica and magnesium stearate. 
Kruta farmaceutska formulacija prema zahtjevima 5 ili 6, koja nadalje sadrži povidon, kroskarmeloza natrij, mikrokristalnu celulozu, koloidnu bezvodnu siliku i magnezij stearat.
and R2 have the same meaning as in formula (V). 
R' i R imaju isto značenje kao u formuli (V).
The handgun holster according to claim 6, wherein a rear wall of the body of the holster comprises an upwardly open slot to facilitate the insertion and withdrawal of the gun. 
Futrola prema bilo kojem patentnom zahtjevu od 1 do 7, naznačena time da se na stražnjoj stijenki tijela (1) futrole nalazi prorez otvoren prema gore kako bi se olakšalo umetanje i izvlačenje vatrenog oružja.
All samples contain 2% DMSO, and the background lacks enzyme but contains all substrates. 
Svi uzorci sadrže 2% DMSO, te pozadinski lososov enzim koji ne sadržava sve supstrate.
is T-R', wherein T is a bond or is an optionally substituted C1-C6 alkylidene chain wherein up to two methylene units are optionally and independently replaced with -O-, -S-, -NR'-, -OCO-, -COO-, -SO2-, or -CO-, and R' is hydrogen, C1-C4-alkyl, or an optionally substituted 5- or 6-membered aryl or heteroaryl group; or R1 is -Si(R')3, R' is hydrogen, C1-C4 alkyl, or an optionally substituted 5- or 6-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što: je T-R', gdje T je veza ili je izborno supstituiran C1-C6alkilidenski lanac, gdje do dvije metilenske jedinice su izborno i neovisno zamijenjen s -O-, -S-, -NR'-, -OCO-, -COO-, -SO2- ili -CO-, a R' je vodik, C1-C4alkil, ili izborno supstituirana 5- ili 6-eročlana arilna ili heteroarilna skupina; ili
MII is a transition metal, and 
MII je prijelazni metal, i
A composition according to claim 1, wherein anti-microbial activity of the honey is equivalent to a solution with a phenol content of at least 10%. 
Obloga u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačena time, da je antimikrobno djelovanje meda ekvivalentno otopini sa sadržajem fenola od najmanje 10 %.
Alternatively, step (b) is carried out under an overpressure within a range of about 200 millibars to about 400 millibars, or within a range of about 250 millibars to about 350 millibars. 
Alternativno, korak (b) se provodi pod tlakom unutar raspona od oko 200 milibara pa do 400 milibara ili od oko 250 milibara pa do 350 milibara.
After culture, IL-2 was predominantly in the form of inclusion bodies. 
Nakon kulture, IL-2 je bio pretežno u obliku inkluzijskih tijela.
A packaging according to any of the preceding claims, wherein the shape of the first and second part are provided by bending or extruding or deep drawing. 
Pakiranje u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time, što su oblik prvog i drugog dijela načinjeni savijanjem ili ekstruzijom ili dubokim izvlačenjem.
In some embodiments, the disorder of skin pigmentation is vitiligo. 
Farmaceutski pripravak za uporabu prema zahtjevu 39, naznačen time da je poremećaj pigmentacije kože, vitiligo.
The method of claim 19 further comprising at least one additional therapeutic agent selected from the group consisting of interferons, ribavirin or its analogs, HCV NS3 protease inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, nucleoside or nucleotide inhibitors of HCV NS5B polymerase, non-nucleoside inhibitors of HCV NS5B polymerase, HCV NS5A inhibitors, TLR-7 agonists, cyclophilin inhibitors, HCV IRES inhibitors, pharmacokinetic enhancers, and other drugs for treating HCV, or mixtures thereof. 
Tvar za uporabu u skladu s patentnim zahtjevom 8 ili 9 obuhvaća najmanje jedan dodatni terapijski agens odabran iz grupe koja se sastoji od interferona, ribavirina ili njegovih analoga, inhibitora HCV NS3 proteaze, inhibitora alfa- glukozidaze 1, hepatoprotektanata, nukleozidnih ili nukleotidnih inhibitora HCV NS5B polimeraze, nenukleozidnih inhibitora HCV NS5B polimeraze, inhibitora HCV NSS5A, agonista TLR-7, inhibitora ciklofilina, inhibitora HCV IRES, farmakokinetičkih pobuđivača, ili drugih lijekova za liječenje HCY ili njihovih smjesa.
An isolated nucleic acid molecule comprising a nucleotide sequence that encodes the heavy chain, or the light chain, of the monoclonal antibody or the antigen-binding portion according to claim 1 . 
Izolirana molekula nukleinske kiseline, naznačena time, da sadrži nukleotidnu sekvencu koja kodira monoklonalno protutijelo ili njegov dio koji se veže na antigen prema bilo kojem od zahtjeva 1 do 6.
Also described herein the method comprises administering to the subject an effective amount of a first therapeutic agent in combination with an effective amount of a second therapeutic agent. 
: ili njegova farmaceutski prihvatljiva sol, naznačeno time da je za upotrebu za liječenje Fabrijeve bolesti, pri čemu navedeno liječenje obuhvaća davanje učinkovite količine prvog terapijskog sredstva u kombinaciji s učinkovitom količinom drugog terapijskog sredstva koje je korisno za liječenje Fabrijeve bolesti.
The method according to claim 1 or 2, wherein said flavonoid is at least one flavonoid glycoside selected from the group consisting of isorhamnetin-diglucoside, quercetin-diglucoside and kaempferol-diglucoside. 
Postupak prema zahtjevu 1 ili 2, naznačen time da navedeni flavonoid je barem jedan flavonoidni glikozid odabran iz skupine koju čine izoramnetin-diglukozid, kvercetin-diglukozid i kempferol-diglukozid.
Process according to any of claims 1 to 12, characterised in that the C8 to C24 aliphatic carboxylic acid(s) are fatty acid(s), especially stearic and/or palmitic and/or myristic and/or lauric acids or mixtures thereof, and most preferably are stearic and/or palmitic acid. 
Postupak prema bilo kojem od zahtjeva 1 do 12, naznačen time da Cg do C», alifatska karboksilna kiselina odnosno alifatske karboksilne kiseline su masne kiseline, posebice stearinska i/ili palmitinska i/ili miristinska i/ili laurinska kiselina ili njihove mješavine, te su najpoželjnije stearinska i/ili palmitinska kiselina.
3 from nucleotide 230 to 251, or the complement of said sequences and wherein the sequence of said second specific probe comprises a nucleotide sequence that has at least 80% sequence identity with SEQ ID No. 
3 od nukleotida 230 do 251, ili komplement navedenih sekvenci i pri čemu sekvenca od navedene druge specifične probe sadrži nukleotidnu sekvencu koja ima barem 80% identičnosti sekvence sa SEQ ID No.
location of the solid component next to the outlet (103) and discharge of the solid component from the outlet (103), wherein said method is carried out without neither the use of chemicals such as emulsifiers or enzymes, nor in vitro culture steps. 
lociranja čvrste komponente pored odvoda (103) 1 pražnjenja čvrste komponente iz odvoda (103), gdje je navedena metoda izvedena bez upotrebe kemikalija kao što su emulgatori ili enzimi, ni koraka in vitro kulture.
A marking device according to claim 6, wherein the respective marking element (71) of the marking members (70) in said set is arranged to apply a mark on a piece of wood by stamping or punching. 
Uređaj za označavanje prema zahtjevu 6 ili 7, naznačen time da odgovarajući element označavanja (71) od dijelova označavanja (70) u spomenutom setu je postavljen za primjenu znaka na komad drveta utiskivanjem ili bušenjem.
The oral solid pharmaceutical composition according to any of the preceding claims, wherein the particle size distribution (d90) of the Lenalidomide particles is in the range of from 2µm to 80µm, preferably from 3µm to 50µm, most preferably from 30µm to 45µm. 
Oralni kruti farmaceutski sastav prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da raspodjela čestica po veličini (d90) čestica Lenalidomida jest u području od 2 µm do 80 µm, pogodno od 3 µm do 50 µm, najpogodnije od 30 µm do 45 µm.
The compound according to Claim 1 or 3, wherein two R10 units are taken together to form an A ring that has a formula chosen from: 
Spoj sukladno zahtjevu 1 ili 3, pri čemu su dvije R'" spojene kako bi formirale prsten A čija je formula odabrana između: Q
The high protein, fruit-flavoured beverage according to any one of the preceding embodiments, wherein the total amount of protein of the denatured whey protein composition is at least 70% (w/w) on a dry-matter basis, preferably at least 75% (w/w) and even more preferably at least 80% (w/w) in a dry weight basis. 
Visokoproteinski napitak s voćnom aromom u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je ukupna količina proteina u pripravku denaturiranog proteina sirutke najmanje 70 % (tež./tež.) na osovi suhe tvari, po mogućnosti najmanje 75 % (tež./tež.), a još poželjnije najmanje 80 % (tež./tež.) na osnovi suhe težine.
A construction according to claim 5 wherein the convex formation continuously melds with the adjacent first and second concave surfaces to provide a continuously undulating curved region. 
Konstrukcija kotača u skladu s patentnim zahtjevom 1, naznačena time da se konveksna formacija (44) neprekidno spaja s graničnim primarnim (41) i sekundarnim (42) konkavnim površinama kako bi se omogućilo neprekidno valovito zakrivljeno područje (40).
Trp Met Examples of production of amino acid substitutions in proteins which can be used for obtaining muteins of IL-18BP polypeptides or proteins, or muteins of viral IL-18BPs, for use in the present invention include any known method steps, such as presented in U.S. Pat. 
Met Primjeri zamjene aminokiselina u proteinima koji se koristite za stvaranje muteina polipeptida ili proteina IL-18BP ili muteina viralnog IL-18BP, a koji su korisni za ovaj izum mogu uključivati bilo koje poznate postupke poput onih koji su navedeni u Američkim patentima 4,959,314; 4,588,585 i 4,737,462 od Mark i sur.; 5,116,943 od Koths i sur.;
w is an integer ranging from 0 to 12; 
w je cijeli broj u rasponu od 0 do 12;
A pharmaceutical composition comprising a proton-binding, crosslinked amine polymer comprising the residue of an amine corresponding to Formula 2: 
Farmaceutski pripravak koji sadrži umreženi aminski polimer koji veže protone i sadrži ostatak amina koji odgovara Formuli 2:
a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:60; and 
CDR2 slijed lakog lanca koji sadrži aminokiselinski slijed SEQ ID NO:60; i iii.
A sunscreen comprising a composition according to any of claims 1 to 5 and at least one agent acting as filter for UV-B and UV-A rays. 
Krema za sunčanje, naznačena time što sadrži pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 51 najmanje jedno sredstvo koje djeluje kao filtar za UV-B i UV-A zrake.
• Mannich bases, formaldehyde, m-xylylenediamine, N-aminoethylpiperazine, blends of N-aminoethylpiperazine with nonylphenol and/or benzyl alcohol, phenalkamines which are obtained in a Mannich reaction from cardanols, aldehydes and amines. 
• Mannichove baze, formaldehid, m-ksililendiamin, N-aminoetilpiperazin, smjese N-aminoetilpiperazina s nonilfenolom i/ili benzil alkoholom, fenalkamini koji su dobiveni Mannichovom reakcijom iz kardanola, aldehida i amina.
The method according to claims 1, wherein the organic solvent used in step c) is propylene glycol. 
Postupak prema zahtjevima 1 ili 2, naznačen time da je organsko otapalo koje se koristi u koraku c) propilenglikol.
if the first Intra mode is not identical to the second Intra mode, then: 
ako prvi Intra mod nije istovjetan drugom Intra modu:
The pharmaceutical formulation according to any one of preceding claims, characterized in that said formulation comprises an amount of said at least one polyoxyalkylene ester of a hydroxy fatty acid ranging from 1% to 20% (w/v), preferably from 2% to 15% (w/v), more preferably from 5% to 15% (w/v), and most preferably from about 5% to about 10% (w/v). 
Farmaceutska formulacija prema bilo kojem od prethodnih zahtjeva, naznačena time, da spomenuta formulacija obuhvaća količinu spomenutog najmanje jednog polioksialkilen-estera od hidroksi masne kiseline u rasponu od 1% do 20% (masa/volumen), poželjno od 2% do 15% (masa/volumen), još bolje od 5% do 15% (masa/volumen) i najbolje od oko 5% do oko 10% (masa/volumen).
a nucleotide sequence encoding at least one glycosyltransferase from a Gram-negative bacterium, wherein said Gram-negative bacterium is Pseudomonas aeruginosa; 
nukleotidni slijed koji kodira najmanje jednu glikozil-transferazu iz Gram-negativne bakterije, gdje je navedena Gram-negativna bakterija Pseudomonas aeruginosa;
A connection assembly according to claim 9, wherein the narrow and wide segments (12, 13) present a cylindrical shape and the intermediate segment (14) presents the shape of a truncated cone. 
Naprava za spajanje u skladu s patentnim zahtjevom 10, naznačena time, da uski i široki segment (12, 13) imaju cilindrični oblik a spojni segment (14) ima oblik krnjeg stošca.
Solutions for parenteral administration may also be prepared as a dry preparation to be reconstituted with a suitable solvent extemporaneously before use. 
Otapala za parenteralno davanje mogu također biti dobivena kao suha kompozicija koja se rekonstituira s pogodnim otapalom bez pripreme prije upotrebe.
In a process for obtaining trifluoroacetyl glatiramer acetate, wherein during the process a batch of a mixture of polypeptides, each of which consists essentially of alanine, Y-benzyl glutamate, tyrosine and trifluoroacetyl lysine is deprotected with a solution of hydrobromic acid in acetic acid, the improvement comprising a step of pretreatment of the solution of hydrobromic acid with a bromine scavenger in order to remove free bromine. 
Postupak za dobivanje smjese trifluoracetil glatiramer acetata, naznačen time, da se za vrijeme postupka, šarži smjese polipeptida, od kojih se svaki sastoji od alanina, Y-benzil glutamata, tirozina i trifluoracetil lizina, skida zaštita otopinom bromovodične kiseline u octenoj kiselini, kod čega poboljšanje obuhvaća uporabu otopine bromovodične kiseline u octenoj kiselini, koja otopina sadrži manje od 1000 ppm nečistoća metalnim ionima i manje od 0,5% slobodnog broma.
Thus, the invention provides a compound as defined above for use in the treatment or prevention of a condition associated with the presence or growth of bacteria in a slow-growing phase or static phase. 
Spoj prema dolje navedenoj formuli I ili II za uporabu u liječenju ili sprječavanju stanja ili poremećaja koji je povezan sa prisutnošću ili rastom mikrobnog biofilma na ili u tijelu živog sisavca
A process according to [7], wherein N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzenesulfonamide is heated and dissolved in a solvent and then crystallized by gradual cooling. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time, da se N-(3-cijano-4-metil-1H-indol-7-il)-3- cijanobenzen-sulfonamid zagrijava i otapa u otapalu i zatim kristalizira postupnim hlađenjem.
R represents independent from each other hydroxyl, cyano, nitro, halogen, alkyl, alkoxy alkylcarbonyl, alkoxycarbonyl, alkylamine, dialkylamine, alkylcarbonylamine, alkylcarbamate Y represents one of the following groups: 
R predstavlja neovisno jedan od drugoga hidroksil, cijano, nitro, halogen, alkil, alkoksi alkilkarbonil, alkoksikarbonil, alkilamin, dialkilamin, alkilkarbonilamin, alkilkarbamat, Y predstavlja jednu od sljedećih skupina: 15
the number of fins is six in number; 
Broj objave europskog patenta:
inserting said block in the aperture of the wall or roof. 
umetanje navedenog bloka (12) u otvor zida (5) ili krova.
The blister pack according to claim 3, in which said at least two areas of continuity have dimensions such that their ratio is between 5:1 and 25:1. 
Blister pakiranje prema 4. zahtjevu, naznačeno time da te najmanje dvije neprekinute površine (3, 4) imaju takve dimenzije da im je omjer između 5:1 125:1.
The fan assembly of claim 1, wherein the silencing member comprises acoustic foam. 
Ventilatorski sustav, gdje dio za stišavanje buke (72) obuhvaća akustičnu pjenu.
Specific examples of commercially available linkers are peptides or polyamides, hydrocarbons, aromatics, heterocyclics, ethers, lipids, cationic or anionic groups, or a combination thereof. 
Specifični primjeri komercijalno dostupnih veznika su peptidi ili poliamidi, ugljikovodici, aromati, heterocikli, eteri, lipidi, kationske ili anionske grupe ili njihova kombinacija.
R9' is selected from the group consisting of C1-9alkyl, aryl, heteroaryl, carbocyclyl and heterocyclyl; and optionally 
je odabran iz skupine koju čine sljedeći: -C1-9alkil, aril, heteroaril, karbociklil i heterociklil;
The method of claim 1, wherein the at least one computer-generated barcode comprise at least one of: a predetermine number of alphanumerical characters, 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što najmanje jedan računalno generirani barkod sadrži najmanje jedno od sljedećeg:
<400> 10 An antibody or binding fragment thereof which specifically binds to a conformational epitope of P-selectin which is within amino acid positions 1-35 of SEQ ID NO:1 and wherein said antibody or binding fragment thereof blocks the binding of PSGL-1 to P-selectin and dissociates preformed P-selectin/PSGL-1 complexes for use for dissociation of preformed P-selectin/PSGL-1 complexes in the treatment of an inflammatory or thrombotic condition or disorder in a subject in need thereof. 
Protutijelo ili njegov vežući fragment, naznačen/o time, da se specifično veže na konformacijski epitop od P- selektina koji je unutar aminokiselinskih pozicija od 1-35 od SEQ ID NO: 1 i pritom navedeno protutijelo ili njegov fragment za vezanje blokira vezanje PSGL-1 na P-selektin i razdružuje prethodno stvorene komplekse P- selektin/PSGL-1, te služi za uporabu u razdruživanju prethodno stvorenih kompleksa P-selektin/PSGL-1, u liječenju upalnih 1 trombotičkih stanja ili poremećaja kod pojedinca kojemu je to potrebno.
a chimeric Cas9 protein, or a polynucleotide encoding said chimeric Cas9 protein, wherein said chimeric Cas9 protein comprises a modified Cas9 protein having reduced nuclease activity compared to the corresponding wild-type Cas9, and comprises a heterologous polypeptide that: 
(b) kimerni protein Cas9, ili polinukleotid koji kodira navedeni kimerni protein Cas9, pri čemu navedeni kimerni protein Cas9 obuhvaća modificirani protein Cas9 koji ima smanjeno djelovanje nukleaze u usporedbi s odgovarajućim divljim tipom Cas9, te obuhvaća heterologni polipeptid koji:
The process of claim 15 or claim 16, further comprising preparing the compound of Formula II: by a process comprising reacting a compound of Formula IIa: with a compound of Formula IIb: for a time suitable for preparing a compound of Formula II, wherein X1 is chloro, bromo, or iodo, preferably in the presence of proline, wherein the process preferably further comprises the steps of: 
Postupak prema zahtjevu 15 ili zahtjevu 16, naznačen time da dodatno sadrži pripremanje spoja s formulom II: O CH sa spojem s formulom IIb: lib tijekom vremena prikladnog za pripremanje spoja s formulom II, pri čemu X, je klor, brom, ili jod, poželjno u prisutnosti prolina, pri čemu postupak poželjno nadalje obuhvaća korake: pripremanje spoja s formulom Ila:
Step (i): reacting N-Boc piperazine of formula 1 
Korak (i): reakciju N-Boc piperazina formule 1
Accordingly, in one aspect, this invention is directed to a method of preparing a compound of formula (I): or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof; 
-CF3 om ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese; naznačen time što se postupak sastoji u: a) obradi spoja formule (7): jej nr Q
reacting a compound of the formula (II): wherein, 
(i) gdje: reakcije spoja formule (II):
The method of claim 25 further comprising making the first compartment of the containment vessel a positive pressure relative to the second compartment such that at least one component of the solution is forced across the semi-permeable portion of the containment vessel. 
Postupak u skladu s patentnim zahtjevom 16, naznačen time što se sastoji u stavljanju prvog odjeljka posude za držanje pod pozitivni tlak u odnosu na drugi odjeljak, tako da se najmanje jednu komponentu otopine potjera kroz polupropusni dio posude za držanje.
n is an integer of 1 or 2, and 
X predstavlja -S-; o n je cijeli broj 1 ili 2, i
A pharmaceutical composition comprising simvastatin and ezetimibe, wherein the use of stabilizing agents, particularly antioxidants, is omitted. 
Farmaceutski pripravak, naznačen time što sadržava simvastatin i ezetimib, u koji nisu uključeni antioksidanti.
The operator could, by hand, uncap bottle 20, and connect it to receiver 30. 
Operater može ručno otvoriti bocu 20 1 priključiti je na nosač 30.
After placement of the reinforcements 23, the fill-material 22 is poured on the floor elements 18, on the profiles 19, on the upper side of the wall elements 2 and the columns positioned below. 
HR P20080681 T3 23, materijal za ispunjavanje 22 se lijeva na podne elemente 18, na profile 19, na gornju stranu zidnih elemenata 2 i na ispod postavljene stupove.
The slurry of claim 1, wherein the lithium-doped potassium silicate comprises potassium and lithium in a ratio of 3:1 to 20:1 by weight as K2O:Li2O, and further wherein the ratio of silicate to potassium is in a ratio of 2:1 to 3:1 by weight as SiO2:K2O. The slurry of claim 2, wherein the lithium-doped potassium silicate comprises potassium and lithium in the ratio of 7:1 to 11:1 by weight as K2O:Li2O, and further wherein the ratio of silicate to potassium is of 2.4:1 to 2.8:1 by weight as SiO2:K2O. 
Pripravak vodene suspenzije za proizvodnju premaza na supstratu, koji sadrži: vezivo koje sadrži vodenu otopinu kalijevog silikata dopiranog litijem, te je vezivo naznačeno time što nema kroma; i aluminijev prah ili prah aluminijeve legure uključen u vezivo, pri čemu su aluminijev prah ili prah aluminijeve legure i vezivo sadržani kao jednodijelni pripravak, aluminijev prah ili prah aluminijeve legure i vezivo sadržani su u unaprijed određenom masenom omjeru; pri čemu kalijev silikat dopiran litijem sadrži kalij i litij u omjeru od 7:1 do 11:1 masenih kao K20:1120, te pri čemu je omjer silikata prema kaliju od 2.4:1 do 2.8:1 masenih kao SiO2:K20.
The meglitinides are benzoic acid derivatives represent a novel class of insulin secretagogues. 
Meglitinidi su derivati benzojeve kiseline prikazani kao nova skupina sekretagoga inzulina.
wherein Ra is hydrogen or methyl; or a pharmaceutically acceptable salt or solvate thereof. 
il pri čemu R, je vodik ili metil; ili njegove farmaceutski prihvatljive soli ili solvati.